medigraphic.com
Centro Universitario de Ciencias de la Salud de la Universidad de Guadalajara y del OPD Hospitales Civiles de Guadalajara

2005, Number s1

<< Back Next >>

Inv Salud 2005; 7 (s1)

Hepatitis B Virus: A Worldwide Health Problem

Román MSM, Vázquez VDM, Panduro CA

Language: Spanish
References: 30
Page: 6-11
PDF size: 196.61 Kb.


ABSTRACT

Hepatitis B virus (HBV) causes acute and chronic infection, which may progress to cirrhosis and hepatocelullar carcinoma. It is the 10th major cause of death worldwide. Man is the natural host of HBV and it is transmitted by 4 modes of transmission, perinatal (carrier mother to newborn), percutaneous, sexual and parenteral. Seroprevalence of HBsAg, the serological marker of infection, is heterogeneous and varies enormously worldwide (high, >8%; intermediate, 2-7.9%; low, < 2%). It is common that in the same geographical region, different seroprevalences coexist. The risk of infection and the mode of transmission are also distinct from one endemicity region to another. It is important to understand this epidemiological behaviour in order to determine prevention, control and treatment measures for the spectrum of clinical outcomes of HVB infection. Mexico is a country of low endemicity. According to actual seroprevalence data of HVB infection, at least 0.5 to 1.4 million persons have evidence of hepatitis B infection; cirrhosis is the 4th cause of death and hepatocellular carcinoma incidence is low in our country. This epidemiological profile is different of that of other countries such as Asia or United States, and requires further research.


REFERENCES

  1. World Health Organization, Dept. of Communicable Disease Surveillance and Response 2002, Hepatitis B,disponible en www.who.int/csr/disease/hepatitis/en/Hepatitis_who cdscsrlyo2002_2.pdf

  2. World Health Organization, Fact Sheet No. 204, 2000, disponible en: www.who.int/medicentre/factsheets/fs204/en/print.html 3. Blumberg, BS. “Hepatitis B virus, the vaccine, and the control of primary cancer of the liver”. Proc Natl Acad Sci, 1997;94:7121-7125.

  3. Seeger C, Mason WS. “Hepatitis B Virus Biology”. Microbiology and Molecular Biology Reviews, 2000;64(1):51-68.

  4. Aggarwal R, Ranjan P. “Preventing and treating hepatitis B infection”. BMJ, 2004;329:1080-1086.

  5. Walsh K, Alexander GJM. “Update on chronic viral hepatitis”. Postgrad Med J, 2001;77:498-505.

  6. Ganem D, Prince AM. “Hepatitis B virus infection-Natural History and Clinical Consequences”. N Engl J Med, 2004;350:1118-29.

  7. Ryder SD, Beckingham IJ. “Chronic viral hepatitis”. BMJ, 2001;322:219-221.

  8. Schiff ER. “Update in Hepatology”. Ann Int Med, 130(1):52-57.

  9. Valla D. “EASL International Consensus Conference on Hepatitis B”. “13-14 September, 2002 Geneva, Switzerland” J Hepatol, 2003;38:533-540.

  10. Lok AS, McMahon BJ. “Chronic Hepatitis B”. Hepatology, 2001;34(6):1225-1241.

  11. World Health Organization “Hepatitis B vaccines”. Weekly epidemiol record, 2004;28(79):253-264. disponible en: www.who.int/wer

  12. CDC y PKIDS “Hepatitis B en Niños. Informe de PKID sobre hepatitis pediátrica”, disponible en: www.pkids.org/Spa phrwhatishbv.pdf

  13. 14.World Health Organización “Hepatitis B vaccine, Immunization, Vaccines and Biologicals”. 2003. Disponible en: www.who.int/vaccines/en/hepatitisb.shtml

  14. Alter MJ “Epidemiology of Hepatitis B in Europe and Worldwide”. EASL International Consensus Conference on Hepatitis B 2002. J Hepatology, 2003;39(Suppl 1):64-9.

  15. Mahoney FJ “Update on diagnosis, management, and prevention of Hepatitis B virus infection”. Clin Microbiol Rev, 1999;12(2):351-366.

  16. Lavanchy D. “Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures”. J Viral Hepatitis, 2004;11:97-107.

  17. Lee WM. “Hepatitis B Virus Infection”. N Engl J Med, 1997;337:1733-1745.

  18. Patlak M, Blumberg B, Hilleman M, Rutter W. “The Hepatitis B story”, disponible en: www.beyonddiscovery.org

  19. World Health Organization. The World Health Report 2004. World Health Organization, Geneva, Switerland, disponible en:www.who.int/wer/en

  20. Medley GF, Lindop, NA, Edmundo J, Nokes, J. “Hepatitis B virus endemicity: heterogeneity, catastrophic dynamics and control”. Nature Med, 2001;7(5):619-624.

  21. Fay OH. “Hepatitis B in Latin America: epidemiological patterns and eradication strategy” Vaccine, 1990;8(Suppl 1):S100-S106.

  22. Torres JR, Machado IV. “Special aspects of hepatitis B and delta virus infection in Latin America”. Infect Dis Clin North Am, 1994;8(1):13-27.

  23. Organización Panamericana de la Salud, La Salud en las Américas. 2002;I:480.

  24. Torres JR. “Hepatitis B and hepatitis delta virus infection in South America”. Gut, 1996;38(Suppl):48-55.

  25. Silveira TR, da Fonseca JC, Rivera L, Fay OH, Tapia R, Santos JI, Urdenata E, Costa Clemens SA. “Hepatitis B seroprevalence in Latin America”, Rev Panam Salud Pública/Pan am J Public Health 1999;6(6):378-383.

  26. Tanaka J. “Hepatitis B epidemiology in Latin America”. Vaccine, 2000;18:S17-S19.

  27. Reporte de Mortalidad 2002, Dirección General de Información en Salud. Secretaria de Salud, México disponible en: www.ssa.gob.mx

  28. Vivas Arceo C, Bastidas Ramírez BE, Panduro A. “Hepatocelullar carcinoma es rarely present in Western Mexico”. Hepatol Res, 1999;16:26-35.

  29. Anónimo. “Avances en la lucha contra la hepatitis B”. Rev Panam Salud Publica, 1997;1(4):333-334.

  30. GlaxoSmithKline “Hepatitis B” disponible en: http://www.worldwidevaccines.com/hepatitis_b/epidemiology.asp




2020     |     www.medigraphic.com